重组人干扰素α-2b治疗疱疹性咽峡炎的疗效观察  

Efficacy of recombinant human interferon α-2b in treatment of herpes angina

作　　者：贾庆岭[1] 申艺坤 杨新利[2] 孟军丽 贾炎 张建 郭艳峰[6] JIA Qing-ling SHEN Yi-kun YANG Xin-li MENG Jun-li JIA Yan ZHANG Jian GUO Yan-feng(Department of Eastern Emergency Department of Dermatology Department of Second Neurosurgery, Handan First Hospital, Handan 056002 ,Hebei, China CT Room, MCH of Handan, Handan 056001, Hebei, China Department of ENT, Fifth Minmetals Hanxing Workers Gerneral Hospital, Handan 056002, Hebei, China Department of Obstetrics and Gynecology, MCH of Yongnian County, Handan 057150, Hebei, China)

机构地区：[1]邯郸市第一医院东区急诊科,河北邯郸056002 [2]邯郸市第一医院皮肤科,河北邯郸056002 [3]邯郸市妇幼保健院CT室,河北邯郸056001 [4]五矿邯邢职工总医院五官科,河北邯郸056002 [5]永年县妇幼保健院妇产科,河北邯郸057150 [6]邯郸市第一医院神外二科,河北邯郸056002

出　　处：《生物医学工程与临床》2017年第3期305-307,共3页Biomedical Engineering and Clinical Medicine

基　　金：河北省2017年度医学科学研究重点课题(20171088)

摘　　要：目的探讨重组人干扰素α-2b喷雾剂局部外用与重组人干扰素α-2b注射液雾化吸入两种方法在治疗疱疹性咽峡炎患儿中的不良反应及临床疗效,为疱疹性咽峡炎患儿提供更好的治疗方案。方法选择2015年8月至2016年8月在邯郸市第一医院就诊的120例疱疹性咽峡炎患儿,按照数字表随机法将患儿分为2组,观察组60例(男性32例,女性28例;平均年龄4.12岁;平均病程3.09 d),对照组60例(男性30例,女性30例;平均年龄3.83岁;平均病程3.51 d)。对照组在常规治疗基础上给予重组人干扰素α-2b喷雾剂局部外用(10 mL∶1×10~6 IU,120喷/瓶);观察组在常规治疗基础上给予重组人干扰素α-2b注射液雾化吸入(体质量<10 kg患儿予以每次10~6 IU,>10 kg患儿予以每次2×10~6 IU)。治疗3~5 d后比较两组患儿临床症状消失时间、治疗的总有效率及不良反应。结果观察组显效33例,有效率95.0%;对照组显效27例,有效率91.7%。观察组与对照组比较,差异无统计学意义(χ~2=1.408,P>0.05)。观察组体温恢复正常的时间和疱疹消退时间较对照组明显缩短[(1.4±0.9)d vs(2.4±1.0)d,(2.3±1.3)d vs(3.4±1.8)d];两组比较,差异有统计学意义(P<0.05)。两组不良反应发生率为2.50%,3例中观察组2例,对照组1例。结论重组人干扰素α-2b注射液雾化吸入可在短时间内缓解临床症状,适宜应用于临床症状较重患儿;重组人干扰素α-2b喷雾剂局部外用简单、易操作,在症状较轻患儿依从性好,值得临床推广应用。Objective To investigate the adverse reactions and effect of topical application of recombinant human interferon alpha-2b spray and nebulization of interferon alpha-2b injection for herpes angina in children, and provide better treatment options. Methods From August 2015 to August 2016, a total of 120 cases with herpes angina were enrolled, which were randomly divided into 2 groups（n = 60） by number tab method. The observation group included 32 males and 28 females, mean age of 4.12 years old, and mean duration of 3.09 days, which was given interferon alpha-2b injection inhalation on the basis of conventional treatment（body weight 〈 10 kg for 10^6 IU/, 〉 10 kg for 2 × 10^6 IU/）. The control group included 30 males and 30 females; mean age of 3.83 years old, and mean duration of 3.51 days, which was given routine treatment based on recombinant human interferon alpha-2b spray topical application（10 mL ： 1 × 10^6 IU, 120 spray/bottle）; The clinical symptoms disappeared time, total effective rate and adverse reactions between 2 groups were compared after treatment for 3 - 5 days. Results In observation group, 33 cases were markedly effective with effective rate was 95.0 %; In control group was 27 cases, the effective rate was 91.7 %, the difference was no statistically significant between 2 groups（Х^2 = 1.408, P 〉 0.05）. The time of body temperature returned to normal and herpea subsidise in observation group was significantly shorter than those in control group[（1.4 ± 0.9） days vs （2.4 ± 1.0） days, （2.3 ± 1.3） days vs （3.4 ± 1.8） days], the difference was statistically significant between 2 groups （P 〈 0.05）. The incidence of adverse reactions was 2.50 %, 2 cases in observation group and 1 in control group. Conclusion In- terferon alpha-2b injection inhalation could relieve clinical symptoms in short time, which suitable for children with more severe clinical symptoms. The recombinant human interferon alpha-2b topical spray is simple and easy in children with mild

关 键 词：疱疹性咽峡炎 干扰素 雾化吸入 

分 类 号：R766.12[医药卫生—耳鼻咽喉科]